S. Breisch

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial

Sarah A. Frech, Herbert L. DuPont, A. Louis Bourgeois et al. · The Lancet · 2008 · 204 citations

Microbial Toxin, Antimicrobial Susceptibility, Heat-labile Toxin +7

Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis

C. E. Langan, R. Cranfield, S. Breisch et al. · Journal of Antimicrobial Chemotherapy · 1997 · 62 citations

Grepafloxacin 600, Grepafloxacin Doses, Antimicrobial Susceptibility +15

Efficacy and Safety of a 10-Day Course of 400 or 600 Milligrams of Grepafloxacin Once Daily for Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis: Comparison with a 10-Day Course of 500 Milligrams of Ciprofloxacin Twice Daily

Sanford Chodosh, S. Lakshminarayan, Herbert Swarz et al. · Antimicrobial Agents and Chemotherapy · 1998 · 62 citations · Full text

Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia

S Topkis, Herbert Swarz, S. Breisch et al. · Clinical Therapeutics · 1997 · 23 citations

Community-acquired Pneumonia, Grepafloxacin 600, Antibiotics +5